These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 20137477

  • 1. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ, Wang B, Yang J, Xuan M, Song LG, Li H, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Tong XC, Jia Y.
    Chin Med J (Engl); 2009 Dec 20; 122(24):2933-8. PubMed ID: 20137477
    [Abstract] [Full Text] [Related]

  • 2. [A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].
    Zhang XZ, Song LG, Wang B, Yang J, Li H, Xuan M, Lei T, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Xie HB, Tong JC.
    Zhonghua Nei Ke Za Zhi; 2010 Aug 20; 49(8):662-6. PubMed ID: 20979784
    [Abstract] [Full Text] [Related]

  • 3. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC.
    Chin Med J (Engl); 2013 Feb 20; 126(3):457-63. PubMed ID: 23422107
    [Abstract] [Full Text] [Related]

  • 4. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L, Yang M, Liu D, Guo C, Li L, Yang G.
    Exp Clin Endocrinol Diabetes; 2012 Jun 20; 120(6):361-6. PubMed ID: 22639400
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 20; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA.
    Bone; 2013 Mar 20; 53(1):160-6. PubMed ID: 23234813
    [Abstract] [Full Text] [Related]

  • 7. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun 20; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 8. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 20; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 9. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
    J Bone Miner Res; 2000 May 20; 15(5):944-51. PubMed ID: 10804025
    [Abstract] [Full Text] [Related]

  • 10. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M, Balducci S, Schiappoli A, Caliumi C, Petramala L, Cerci S, Cotesta D, D'Erasmo E, Letizia C.
    Ann Ital Med Int; 2003 May 20; 18(2):89-98. PubMed ID: 12886826
    [Abstract] [Full Text] [Related]

  • 11. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 20; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 12. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.
    Zhang L, Li L, Yang M, Xu K, Boden G, Yang G.
    Osteoporos Int; 2013 Mar 20; 24(3):1107-12. PubMed ID: 22419369
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb 20; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 14. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan 20; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 15. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 20; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 16. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr 20; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 17. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 20; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 20; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 19. Comparison between recombinant human parathyroid hormone (1-34) and elcatonin in treatment of primary osteoporosis.
    Yang Y, Zhang XJ, Zhu XJ, Zhang L, Bao MJ, Xian Y, Wu JC, Liu LM, Li PQ.
    Asian Pac J Trop Med; 2015 Jan 20; 8(1):79-84. PubMed ID: 25901930
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 20; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.